ClinicalTrials.gg
CompletedNCT05559905Updated Jul 18, 2025Results posted

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

A Phase 2 interventional study of Molnupiravir and Placebo in Respiratory Syncytial Virus, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a study of molnupiravir (MK-4482) in healthy participants who have been inoculated with an experimental Respiratory Syncytial Virus (RSV) [RSV-A Memphis 37b]. It is hypothesized that treatment with the drug MK-4482 (molnupiravir) will reduce the peak viral load (PVL) in the participant compared to placebo when given either before or after RSV-A Memphis 37b inoculation.

Read the detailed description

Participants arrive at the study center for check-in between Day -3 and Day -1. Participants receive the assigned treatment beginning on Day -1. On Day 0, all participants receive viral inoculation with RSV-A Memphis 37b. All participants depart on Day 12 and follow-up is continued until Day 28.

The study is designed with the following arms:

  • Panel A: Molupiravir Prophylaxis - in this arm, participants receive molupiravir beginning on Day -1, are incoluated with RSV-A Memphis 37b on Day 0, and continue receiving molnupiravir for a total of 5 days before switching to placebo through Day 10.
  • Panel B: Molupiravir Triggered Treatment - in this arm, participants receive placebo beginning on Day -1 until testing positive for RSV. Participants are inoculated with RSV-A Memphis 37b on Day 0. When participants test positive for RSV, they switch to molnupiravir for a total of 5 consecutive days before switching back to placebo through Day 10. If participants in this arm do not test positive for RSV by Day 5, they automatically switch to molnupiravir through Day 10.
  • Panel C: Placebo - in this arm, all participants receive placebo beginning on Day -1, are inoculated with RSV-A Memphis 37b on Day 0, and continue receiving placebo through Day 10.
02

Conditions studied

  • Respiratory Syncytial Virus
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in good health based on medical history, physical examination, vital sign measurements, spirometry, and (ECGs) performed before randomization.
  • Has a total body weight ≥50 kg and (BMI) ≥18 kg/m\^2 and ≤35 kg/m\^2.
  • For males, agrees to abstain from heterosexual intercourse OR use unless confirmed to be azoospermic during the study and for 90 days after.
  • For females, is not pregnant or breastfeeding, AND is either not a woman of (WOCBP) or is a WOCBP AND uses a highly effective contraceptive (low user dependency OR a user dependent hormonal method in combination with a barrier method), has a negative highly sensitive pregnancy test at screening, and has medical, menstrual, and recent sexual activity history reviewed by the investigator to decrease risk of early undetected pregnancy.

Exclusion criteria

Exclusion Criteria:

  • Has a history of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to the first study visit.
  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Has a history of resolved depression and/or anxiety 1 or more years ago may be included at the discretion of the investigator.
  • Has a history of cancer ().
  • Has a history of rhinitis (including hay fever) which is clinically active or history of moderate to severe rhinitis, or history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal on an at least weekly basis, within 30 days of admission to quarantine.
  • Has a history of atopic dermatitis/eczema which is clinically severe and/or requiring moderate to large amounts of daily dermal corticosteroids.
  • If the reporting physician has diagnosed migraine can be included, provided there are no associated neurological symptoms such as hemiplegia or visual loss.
  • If there is a physician diagnosed mild Irritable Bowel Syndrome not requiring regular treatment, can be included at the discretion of the investigator.
  • Uses or anticipates use during study of herbal supplements within 7 days prior to Viral Challenge, any cytochrome P450 (CYP450)-inhibiting medications within 21 days prior to Viral Challenge, any over-the-counter medications (eg, ibuprofen) within 7 days prior to Viral Challenge, or any systemic anti-viral administration within 4 weeks of Viral Challenge/first dosing of study medication.
  • Has evidence of receipt of vaccine within the 4 weeks prior to the planned date of viral challenge/first dosing with study medication (whichever occurs first).
  • Intends to receive any vaccine before the last study visit.
  • Has received any drug within 3 months or 5 half-lives (whichever is greater) prior to the planned date of viral challenge/first dosing with study medication (whichever occurs first).
  • Has received ≥3 investigational drugs in the past 12 months.
  • Has had a prior inoculation with a virus from the same family as the challenge virus.
  • Has smoked ≥10 pack years at any time (one pack of 20 cigarettes a day for 10 years).
  • Has a recent history or presence of alcohol addiction, or excessive use of alcohol (weekly intake in excess of 28 units alcohol; 1 unit being a half glass of beer, a small glass of wine or a measure of spirits), or excessive consumption of xanthine-containing substances (eg, daily intake in excess of 5 cups of caffeinated drinks such as coffee, tea, cola).
  • Has a lifetime history of anaphylaxis and/or a lifetime history of severe allergic reaction.
  • Has any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and, in particular, any of the nasal assessments or viral challenge.
  • Has any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first study visit and/or history of being hospitalized due to epistaxis on any previous occasion.
  • Has had any nasal or sinus surgery within 3 months of the first study visit.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Panel A: Molnupiravir Prophylaxis

    Participants received molnupiravir 800 mg every 12 hours for 5 days beginning on Day -1, and are inoculated with RSV-A Memphis 37b on Day 0. Participants switch to placebo beginning on the evening of Day 4 to the morning of Day 10.

    Drug: Molnupiravir · Drug: Placebo · Biological: RSV A Memphis 37b

  • Experimental
    Panel B: Molnupiravir Triggered Treatment

    Participants received placebo on Day -1, are inoculated with RSV-A Memphis 37b on Day 0, and continue to receive placebo until testing positive for RSV. Participants then received 800 mg of molnupiravir every 12 hours for 5 days.

    Drug: Molnupiravir · Drug: Placebo · Biological: RSV A Memphis 37b

  • Placebo comparator
    Panel C: Matched Placebo

    Participants received placebo beginning on Day -1, are inoculated with RSV-A Memphis 37b on Day 0, and continue receiving placebo until the morning of Day 10.

    Drug: Placebo · Biological: RSV A Memphis 37b

Interventions

  • Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.

    Also known as: MK-4482

  • DrugPlacebo

    Placebo capsule matched to molnupiravir taken twice daily by mouth.

  • BiologicalRSV A Memphis 37b

    RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of \~4 Log10 plaque forming units (PFUs).

06

What researchers measure

Primary outcomes

  1. Panel A vs Panel C: Peak Viral Load (PVL) Determined by Viral Quantitative Culture

    PVL was defined as the maximum viral load during a specified time period. PVL determined by viral quantitative culture (plaque assay) was measured from Day 2 up to Day 12 (end of participant quarantine). PVL (on the log10 scale) of RSV A Memphis 37b determined by viral quantitative culture (plaque assay) between Day 2 and Day 12 am after intranasal inoculation (Day 0) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model.

    Time frame: From Day 2 up to Day 12

  2. Panel B vs. Panel C: Area Under the Viral Load-time Curve (VL-AUC) Determined by Viral Quantitative Culture

    VL-AUC between Day 2 and Day 12 after intranasal inoculation (Day 0) was computed for each participant, based on RSV viral load determined by viral quantitative culture (plaque assay) from nasal wash samples collected twice daily (morning and evening). In order to calculate the AUC, the actual time that the assessment was collected was used within the AUC calculation. VL-AUC (on the log10 scale) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B (treatment) and Panel C (placebo) were included in the model. For both panels, only the participants with RSV infection were included.

    Time frame: From Day 2 up to Day 12

Secondary outcomes

  1. All Panels: Number of Participants Who Experienced ≥1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE is reported.

    Time frame: From Day -1 up to Day 28

  2. All Panels: Number of Participants Who Experienced ≥1 Serious AE (SAE)

    An SAE is any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires hospitalization or prolongs existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly or birth defect; or is another important medical event such as invasive/malignant cancers or substance abuse/dependency. The number of participants who experienced an SAE is reported.

    Time frame: From Day -1 up to Day 28

  3. All Panels: Number of Participants Who Experienced ≥1 Viral Challenge-Related AE

    A viral challenge-related AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that was considered related to the viral challenge (inoculation). The number of participants who experienced AEs related to the viral challenge from viral challenge (Day 0) up to the Day 28 follow-up is reported.

    Time frame: From Day 0 up to Day 28

  4. All Panels: Number of Participants Who Experienced ≥1 Viral Challenge-Related SAE

    A viral challenge-related SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening; required hospitalization or prolonged existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly or birth defect; or was another important medical event, that was considered related to the viral challenge (inoculation). The number of participants who experienced SAEs related to the viral challenge from viral challenge (Day 0) up to the Day 28 follow-up is reported.

    Time frame: From Day 0 up to Day 28

  5. All Panels: Number of Participants Using Concomitant Medications From Viral Challenge Through Day 28

    Concomitant medications were defined as any prescription medications, over the counter drugs or dietary supplements that a participant happened to be taking while on study, in addition to molnupiravir. The number of participants using concomitant medications from viral challenge (Day 0) up through Day 28 is reported.

    Time frame: From Day 0 up to Day 28

  6. Panel A vs. Panel C: VL-AUC Determined by Viral Quantitative Culture

    VL-AUC between Day 2 and Day 12 after intranasal inoculation (Day 0) was computed for each participant, based on RSV viral load determined by viral quantitative culture (plaque assay) from nasal wash samples collected twice daily (morning and evening). In order to calculate the AUC, the actual time that the assessment was collected was used within the AUC calculation. VL-AUC (on the log10 scale) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model.

    Time frame: From Day 2 up to Day 12

  7. Panel A vs. Panel C: VL-AUC Determined by Real-time Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

    VL-AUC between Day 2 and Day 12 after intranasal inoculation (Day 0) was computed for each participant, based on RSV viral load determined by qRT-PCR from nasal wash samples collected twice daily (morning and evening). In order to calculate the AUC, the actual time that the assessment was collected was used within the AUC calculation. VL-AUC (on the log10 scale) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model.

    Time frame: Day 2 up through Day 12

  8. Panel A vs. Panel C: PVL Determined by qRT-PCR

    PVL was defined as the maximum viral load during a specified time period. PVL as determined by qRT-PCR was measured starting from Day 2 up to planned discharge from quarantine (Day 12 am). Nasal wash samples were collected and tested for RSV viral load by qRT-PCR twice daily from Day 2 through Day 11. A single nasal wash sample for RSV viral load by qRT-PCR was collected on Day 12. PVL by qRT-PCR was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model.

    Time frame: Day 2 up through Day 12

  9. Panel A vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores (TSS-AUC)

    Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). Total symptom scores (TSS) ranged from 0 to 31, with higher scores indicating greater symptom severity. TSS were used to calculate the AUC for each participant based on the available non-missing calculated total symptom scores between Day -1 until Day 12 (quarantine discharge) using the Trapezoidal rule. TSS-AUC was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model. TSS-AUC measured from 10 symptoms within the graded symptom scoring was reported.

    Time frame: From Day -1 up to Day 12

  10. Panel A vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores Change From Baseline (TSS-AUC-CFB)

    Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("absence") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. TSS were used to calculate the AUC for each participant based on the available non-missing calculated total symptom scores between Day -1 until Day 12 (quarantine discharge) using the Trapezoidal rule. TSS-AUC-CFB was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model. TSS-AUC-CFB was defined as the change from baseline in TSS-AUC from Day -1 up to Day 12. TSS-AUC-CFB measured from 10 symptoms within the graded symptom scoring was reported.

    Time frame: Baseline (Day -1) and up to Day 12

  11. Panel A vs. Panel C: Peak Total Symptom Scores

    Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. The highest TSS (defined as the sum of all 10 individual composite symptoms) was summarized by treatment group and analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model. Peak TSS measured from 10 symptoms within the graded symptom scoring was reported.

    Time frame: From Day -1 up to Day 12

  12. Panel A vs. Panel C: Peak Daily Symptom Score

    Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. The highest total symptom score recorded on each day, across the three assessments, for each participant was summarized descriptively by treatment group and assessment day. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis. Peak daily sums of symptom score measured from 10 symptoms within the graded symptom scoring were reported for Panels A and C.

    Time frame: From Day 2 up to Day 12

  13. Panel A vs. Panel C: Percentage of Participants With Respiratory Syncytial Virus (RSV) Infection Based on qRT-PCR

    A qRT-PCR-confirmed RSV infection was defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent samples over 2 days), from Day 2 up to Day 12. The number of participants with qRT-PCR-confirmed RSV infection is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

    Time frame: From Day 2 up to Day 12

  14. Panel A vs. Panel C: Percentage of Participants With RSV Infection Based on Cell Culture Measurement of Nasal Sample

    RSV infection based on cell culture measurement was defined as at least one positive (≥ LLOQ) cell culture measurement in nasal swab samples. The percentage of participants with at least one positive (≥ LLOQ) cell culture measurement in nasal swab samples is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

    Time frame: From Day 2 up to Day 12

  15. Panel A vs. Panel C: Percentage of Participants With qRT-PCR Confirmed Symptomatic RSV Infection

    Symptomatic RSV infection was defined as 2 quantifiable (≥LLOQ) qRT-PCR measurements reported on 2 or more days and either one or more clinical symptoms of any grade from two different categories in the symptom scoring system (upper respiratory, lower respiratory, systemic) or one grade 2 symptom from any category. The percentage of participants with qRT-PCR-confirmed symptomatic RSV infection is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

    Time frame: From Day 2 up to Day 12

  16. Panel A vs. Panel C: Percentage of Participants With qRT-PCR Confirmed Moderately Severe Symptomatic RSV Infection

    Moderately severe symptomatic RSV infection was defined as 2 quantifiable (≥LLOQ) qRT-PCR measurements reported on 2 or more consecutive days and any symptom scores of grade ≥2 at a single time point. The percentage of participants with qRT-PCR-confirmed moderately severe symptomatic RSV infection is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

    Time frame: From Day 2 up to Day 12

  17. Panel A vs. Panel C: Percentage of Participants With Culture-Confirmed Symptomatic RSV Infection

    Culture-confirmed symptomatic RSV infection was defined by 1 quantifiable (≥LLOQ) cell culture measurement from Day 2 up to Day 12, and either one or more clinical symptoms of any grade from two different categories in the symptom scoring system (upper respiratory, lower respiratory, systemic) or one grade 2 symptom from any category. The percentage of participants with culture confirmed symptomatic RSV infection is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

    Time frame: From Day 2 up to Day 12

  18. Panel B vs. Panel C: PVL Determined by Viral Quantitative Culture

    PVL was defined as the maximum viral load during a specified time period. PVL as determined by viral quantitative culture was measured starting from Day 2 up to planned discharge from quarantine (Day 12 am). PVL (on the log10 scale) of RSV A Memphis 37b determined by viral quantitative culture (plaque assay) between Day 2 and Day 12 am after intranasal inoculation (Day 0) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

    Time frame: From Day 2 up to Day 12

  19. Panel B vs. Panel C: Time to Negative Test by Viral Quantitative Culture

    The time to negative test was defined as length of time in days between the date and time of the first MK-4482 administration to the date and time of first confirmed negative test after peak viral culture measurement. A negative test is a result below the low limit of quantification (LLOQ) by viral quantitative culture (plaque assay). The Kaplan-Meier estimate median in days is reported. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

    Time frame: From Day 2 up to Day 12

  20. Panel B vs. Panel C: VL-AUC Determined by qRT-PCR

    VL-AUC between Day 2 and Day 12 after intranasal inoculation (Day 0) was computed for each participant, based on RSV viral load determined by qRT-PCR from nasal wash samples collected twice daily (morning and evening). In order to calculate the AUC, the actual time that the assessment was collected was used within the AUC calculation. VL-AUC (on the log10 scale) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

    Time frame: From Day 2 up to Day 12

  21. Panel B vs. Panel C: PVL Determined by qRT-PCR

    PVL was defined as the maximum viral load during a specified time period. PVL as determined by qRT-PCR was measured starting from Day 2 up to planned discharge from quarantine (Day 12 am). Nasal wash samples were collected and tested for RSV viral load by qRT-PCR twice daily from Day 2 through Day 11. A single nasal wash sample for RSV viral load by qRT-PCR was collected on Day 12. PVL by qRT-PCR were analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

    Time frame: From Day 2 up to Day 12

  22. Panel B vs. Panel C: Time to Negative Test by qRT-PCR

    The time (days) to confirmed negative test by qRT-PCR was defined as the length of time between the date and time of the first investigational medicinal product (IMP) administration to the date and time of first confirmed undetectable (\<LLOQ) qRT-PCR result after peak qRT-PCR measurement. The time to negative test starting at Day 2 to first confirmed undetectable (\<LLOQ) assessment after peak measure is reported. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

    Time frame: From Day 2 up to Day 12

  23. Panel B vs. Panel C: TSS-AUC

    Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). Total symptom scores (TSS) ranged from 0 to 31, with higher scores indicating greater symptom severity. TSS were used to calculate the AUC for each participant based on the available non-missing calculated total symptom scores between Day -1 until Day 12 (quarantine discharge) using the Trapezoidal rule. TSS-AUC was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B and Panel C are included in the model, and only participants with RSV infection were included in the analysis. TSS-AUC measured from 10 symptoms within the graded symptom scoring was reported.

    Time frame: From Day -1 up to Day 12

  24. Panel B vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores Change From Baseline (TSS-AUC-CFB)

    Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("absence") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. TSS were used to calculate the AUC for each participant based on the available non-missing calculated total symptom scores between Day -1 until Day 12 (quarantine discharge) using the Trapezoidal rule. TSS-AUC-CFB was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B and Panel C are included in the model, and only the participants with RSV infection were included in the analysis. TSS-AUC-CFB was defined as the change from baseline in TSS-AUC from Day -1 up to Day 12. TSS-AUC-CFB measured from 10 symptoms within the graded symptom scoring was reported.

    Time frame: Baseline (Day -1) and up to Day 12

  25. Panel B vs. Panel C: Peak TSS

    Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. The highest total symptom score (defined as the sum of all 10 individual composite symptoms) was summarized by treatment group and analyzed using a linear model with treatment group as a fixed categorical effect. Peak TSS measured from 10 symptoms within the graded symptom scoring was reported for Panels B and C. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

    Time frame: From Day -1 up to Day 12

  26. Panel B vs. Panel C: Peak Daily Symptom Score

    Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. The highest total symptom score recorded on each day, across the three assessments, for each participant was summarized descriptively by treatment group and assessment day. Peak daily sums of symptom score measured from 10 symptoms within the graded symptom scoring were reported for Panels B and C. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

    Time frame: From Day -1 up to Day 12

  27. Panel B vs. Panel C: Time to Symptom Resolution

    Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. Symptom resolution was defined as a participant scoring 0 for the total symptom score for a 24-hour period (e.g., a minimum of three consecutive symptom diary cards, each with a score of 0 after their peak symptom score. The time in days to symptom resolution by treatment group, as measured from 10 symptoms within the graded daily symptom scoring system, was reported. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

    Time frame: From Day -1 up to Day 12

  28. Panels A & B: Maximum Plasma Concentration (Cmax) of N-Hydroxycytidine (NHC)

    NHC is the pharmacologically active moiety of molnupiravir and therefore its primary pharmacokinetic measure. Cmax was defined as the peak concentration of NHC over the dosing interval. Plasma samples were collected at multiple time points pre-and post-administration and used to determine Cmax. Cmax of NHC was reported for participants receiving molnupiravir in Panels A and B.

    Time frame: Day -1: Predose and 12 hours postdose; Days 2, 5, and 6: 12 hours postdose; Days 4 and 7: predose and 0.5, 1.5, 4, 8, and 12 hours postdose

  29. Panels A & B: Time to Maximum Plasma Concentration (Tmax) of NHC

    NHC is the pharmacologically active moiety of molnupiravir and therefore its primary pharmacokinetic measure. Tmax was defined as the time to peak concentration. Plasma samples were collected at multiple time points pre-and post-administration and used to determine Tmax. Tmax of NHC was reported for participants receiving molnupiravir in Panels A and B.

    Time frame: Day -1: Predose and 12 hours postdose; Days 2, 5, and 6: 12 hours postdose; Days 4 and 7: predose and 0.5, 1.5, 4, 8, and 12 hours postdose

  30. Panels A & B: Area Under the Plasma Concentration Curve From 0 to 12 Hours Postdose (AUC0-12) of NHC

    NHC is the pharmacologically active moiety of molnupiravir and therefore its primary pharmacokinetic measure. Plasma samples were collected at multiple time points pre-and post-administration and used to determine the area under the plasma concentration curve from time 0 to 12 hours (AUC0-12). AUC0-12 was reported for participants receiving molnupiravir in Panels A and B.

    Time frame: Day -1: Predose and 12 hours postdose; Days 2, 5, and 6: 12 hours postdose; Days 4 and 7: predose and 0.5, 1.5, 4, 8, and 12 hours postdose

  31. Panels A & B: Trough Concentration (Ctrough) of NHC

    NHC is the pharmacologically active moiety of molnupiravir and therefore its primary pharmacokinetic measure. The trough concentration (Ctrough) was defined as the lowest concentration before the next dose. Plasma samples were collected at multiple time points pre-and post-administration and used to determine Cmax. Ctrough of NHC in plasma was reported for participants receiving molnupiravir in Panels A and B.

    Time frame: Day 2 at 12 hours predose (Panel A) or Day 6 at 12 hours predose (Panel B)

07

Results

Posted May 20, 2024

Participant flow

Participants in the lower quartile for immunogenicity to the RSV A Memphis 37b as determined by a serum microneutralization assay were screened for eligibility for this study.

Participant flow — Overall Study
MilestonePanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Started403640
Started study medication393640
Completed383640
Not completed200
Withdrew: Withdrawal by subject100
Withdrew: Not reported100

Outcome measures

PrimaryPanel A vs Panel C: Peak Viral Load (PVL) Determined by Viral Quantitative Culture

PVL was defined as the maximum viral load during a specified time period. PVL determined by viral quantitative culture (plaque assay) was measured from Day 2 up to Day 12 (end of participant quarantine). PVL (on the log10 scale) of RSV A Memphis 37b determined by viral quantitative culture (plaque assay) between Day 2 and Day 12 am after intranasal inoculation (Day 0) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model.

Time frame:
From Day 2 up to Day 12
Reported as:
Least squares mean · log10 plaque forming units (PFU)/mL
Panel A vs Panel C: Peak Viral Load (PVL) Determined by Viral Quantitative Culture
log10 plaque forming units (PFU)/mLPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs Panel C: Peak Viral Load (PVL) Determined by Viral Quantitative Culture2.55 (1.81 to 3.30)2.84 (2.12 to 3.57)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · ANOVA · p = 0.578 · Difference in least squares mean: -0.29 · 90% CI -1.16 to 0.58
PrimaryPanel B vs. Panel C: Area Under the Viral Load-time Curve (VL-AUC) Determined by Viral Quantitative Culture

VL-AUC between Day 2 and Day 12 after intranasal inoculation (Day 0) was computed for each participant, based on RSV viral load determined by viral quantitative culture (plaque assay) from nasal wash samples collected twice daily (morning and evening). In order to calculate the AUC, the actual time that the assessment was collected was used within the AUC calculation. VL-AUC (on the log10 scale) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B (treatment) and Panel C (placebo) were included in the model. For both panels, only the participants with RSV infection were included.

Time frame:
From Day 2 up to Day 12
Reported as:
Least squares mean · day*log10 PFU/mL
Panel B vs. Panel C: Area Under the Viral Load-time Curve (VL-AUC) Determined by Viral Quantitative Culture
day*log10 PFU/mLPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: Area Under the Viral Load-time Curve (VL-AUC) Determined by Viral Quantitative Culture7.02 (3.91 to 10.14)9.72 (6.93 to 12.50)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · ANOVA · p = 0.201 · Difference in least squares mean: -2.69 · 90% CI -6.17 to -0.79
SecondaryAll Panels: Number of Participants Who Experienced ≥1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE is reported.

Time frame:
From Day -1 up to Day 28
Reported as:
Count of participants · Participants
All Panels: Number of Participants Who Experienced ≥1 Adverse Event (AE)
ParticipantsPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
All Panels: Number of Participants Who Experienced ≥1 Adverse Event (AE)131513
SecondaryAll Panels: Number of Participants Who Experienced ≥1 Serious AE (SAE)

An SAE is any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires hospitalization or prolongs existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly or birth defect; or is another important medical event such as invasive/malignant cancers or substance abuse/dependency. The number of participants who experienced an SAE is reported.

Time frame:
From Day -1 up to Day 28
Reported as:
Count of participants · Participants
All Panels: Number of Participants Who Experienced ≥1 Serious AE (SAE)
ParticipantsPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
All Panels: Number of Participants Who Experienced ≥1 Serious AE (SAE)000
SecondaryAll Panels: Number of Participants Who Experienced ≥1 Viral Challenge-Related AE

A viral challenge-related AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that was considered related to the viral challenge (inoculation). The number of participants who experienced AEs related to the viral challenge from viral challenge (Day 0) up to the Day 28 follow-up is reported.

Time frame:
From Day 0 up to Day 28
Reported as:
Count of participants · Participants
All Panels: Number of Participants Who Experienced ≥1 Viral Challenge-Related AE
ParticipantsPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
All Panels: Number of Participants Who Experienced ≥1 Viral Challenge-Related AE111
SecondaryAll Panels: Number of Participants Who Experienced ≥1 Viral Challenge-Related SAE

A viral challenge-related SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening; required hospitalization or prolonged existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly or birth defect; or was another important medical event, that was considered related to the viral challenge (inoculation). The number of participants who experienced SAEs related to the viral challenge from viral challenge (Day 0) up to the Day 28 follow-up is reported.

Time frame:
From Day 0 up to Day 28
Reported as:
Count of participants · Participants
All Panels: Number of Participants Who Experienced ≥1 Viral Challenge-Related SAE
ParticipantsPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
All Panels: Number of Participants Who Experienced ≥1 Viral Challenge-Related SAE000
SecondaryAll Panels: Number of Participants Using Concomitant Medications From Viral Challenge Through Day 28

Concomitant medications were defined as any prescription medications, over the counter drugs or dietary supplements that a participant happened to be taking while on study, in addition to molnupiravir. The number of participants using concomitant medications from viral challenge (Day 0) up through Day 28 is reported.

Time frame:
From Day 0 up to Day 28
Reported as:
Count of participants · Participants
All Panels: Number of Participants Using Concomitant Medications From Viral Challenge Through Day 28
ParticipantsPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
All Panels: Number of Participants Using Concomitant Medications From Viral Challenge Through Day 28677
SecondaryPanel A vs. Panel C: VL-AUC Determined by Viral Quantitative Culture

VL-AUC between Day 2 and Day 12 after intranasal inoculation (Day 0) was computed for each participant, based on RSV viral load determined by viral quantitative culture (plaque assay) from nasal wash samples collected twice daily (morning and evening). In order to calculate the AUC, the actual time that the assessment was collected was used within the AUC calculation. VL-AUC (on the log10 scale) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model.

Time frame:
From Day 2 up to Day 12
Reported as:
Least squares mean · day*log10 PFU/mL
Panel A vs. Panel C: VL-AUC Determined by Viral Quantitative Culture
day*log10 PFU/mLPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: VL-AUC Determined by Viral Quantitative Culture7.56 (4.95 to 10.17)8.17 (5.64 to 10.70)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · ANOVA · p = 0.736 · Difference in least squares mean: -0.62 · 90% CI -3.65 to 2.42
SecondaryPanel A vs. Panel C: VL-AUC Determined by Real-time Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

VL-AUC between Day 2 and Day 12 after intranasal inoculation (Day 0) was computed for each participant, based on RSV viral load determined by qRT-PCR from nasal wash samples collected twice daily (morning and evening). In order to calculate the AUC, the actual time that the assessment was collected was used within the AUC calculation. VL-AUC (on the log10 scale) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model.

Time frame:
Day 2 up through Day 12
Reported as:
Least squares mean · day*log10 copies/mL
Panel A vs. Panel C: VL-AUC Determined by Real-time Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
day*log10 copies/mLPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: VL-AUC Determined by Real-time Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)17.62 (11.70 to 25.53)19.54 (13.70 to 25.39)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · ANOVA · p = 0.646 · Difference in least squares mean: -1.93 · 90% CI -8.88 to 5.02
SecondaryPanel A vs. Panel C: PVL Determined by qRT-PCR

PVL was defined as the maximum viral load during a specified time period. PVL as determined by qRT-PCR was measured starting from Day 2 up to planned discharge from quarantine (Day 12 am). Nasal wash samples were collected and tested for RSV viral load by qRT-PCR twice daily from Day 2 through Day 11. A single nasal wash sample for RSV viral load by qRT-PCR was collected on Day 12. PVL by qRT-PCR was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model.

Time frame:
Day 2 up through Day 12
Reported as:
Least squares mean · day*log10 copies/mL
Panel A vs. Panel C: PVL Determined by qRT-PCR
day*log10 copies/mLPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: PVL Determined by qRT-PCR4.66 (3.66 to 5.66)4.80 (3.81 to 5.79)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · ANOVA · p = 0.849 · Difference in least squares mean: -0.14 · 90% CI -1.31 to 1.04
SecondaryPanel A vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores (TSS-AUC)

Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). Total symptom scores (TSS) ranged from 0 to 31, with higher scores indicating greater symptom severity. TSS were used to calculate the AUC for each participant based on the available non-missing calculated total symptom scores between Day -1 until Day 12 (quarantine discharge) using the Trapezoidal rule. TSS-AUC was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model. TSS-AUC measured from 10 symptoms within the graded symptom scoring was reported.

Time frame:
From Day -1 up to Day 12
Reported as:
Least squares mean · Scores on a Scale*Days
Panel A vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores (TSS-AUC)
Scores on a Scale*DaysPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores (TSS-AUC)7.5 (4.18 to 10.81)9.59 (6.36 to 12.82)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · ANOVA · p = 0.371 · Difference in least squares mean: -2.09 · 90% CI -5.97 to 1.78
SecondaryPanel A vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores Change From Baseline (TSS-AUC-CFB)

Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("absence") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. TSS were used to calculate the AUC for each participant based on the available non-missing calculated total symptom scores between Day -1 until Day 12 (quarantine discharge) using the Trapezoidal rule. TSS-AUC-CFB was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model. TSS-AUC-CFB was defined as the change from baseline in TSS-AUC from Day -1 up to Day 12. TSS-AUC-CFB measured from 10 symptoms within the graded symptom scoring was reported.

Time frame:
Baseline (Day -1) and up to Day 12
Reported as:
Least squares mean · Scores on a Scale*Days
Panel A vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores Change From Baseline (TSS-AUC-CFB)
Scores on a Scale*DaysPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores Change From Baseline (TSS-AUC-CFB)6.84 (4.03 to 9.66)8.66 (5.92 to 11.41)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · ANOVA · p = 0.360 · Difference in least squares mean: -1.82 · 90% CI -5.11 to 1.47
SecondaryPanel A vs. Panel C: Peak Total Symptom Scores

Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. The highest TSS (defined as the sum of all 10 individual composite symptoms) was summarized by treatment group and analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the model. Peak TSS measured from 10 symptoms within the graded symptom scoring was reported.

Time frame:
From Day -1 up to Day 12
Reported as:
Least squares mean · Scores on a Scale
Panel A vs. Panel C: Peak Total Symptom Scores
Scores on a ScalePanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: Peak Total Symptom Scores2.74 (1.85 to 3.62)3.20 (2.33 to 4.07)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · ANOVA · p = 0.459 · Difference in least squares mean: -0.46 · 90% CI -1.50 to 0.57
SecondaryPanel A vs. Panel C: Peak Daily Symptom Score

Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. The highest total symptom score recorded on each day, across the three assessments, for each participant was summarized descriptively by treatment group and assessment day. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis. Peak daily sums of symptom score measured from 10 symptoms within the graded symptom scoring were reported for Panels A and C.

Time frame:
From Day 2 up to Day 12
Reported as:
Mean · Scores on a Scale
Panel A vs. Panel C: Peak Daily Symptom Score
Scores on a ScalePanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Day 20.8 ± 1.131.1 ± 1.36
Day 30.6 ± 0.880.9 ± 1.24
Day 40.7 ± 0.981.0 ± 1.56
Day 50.8 ± 1.221.4 ± 1.90
Day 61.2 ± 1.412.1 ± 2.82
Day 71.4 ± 1.521.9 ± 3.02
Day 81.7 ± 2.241.8 ± 2.22
Day 91.4 ± 1.671.3 ± 1.90
Day 100.9 ± 1.830.8 ± 1.58
Day 110.7 ± 1.210.5 ± 1.02
Day 120.3 ± 0.760.3 ± 0.56
SecondaryPanel A vs. Panel C: Percentage of Participants With Respiratory Syncytial Virus (RSV) Infection Based on qRT-PCR

A qRT-PCR-confirmed RSV infection was defined as 2 quantifiable (≥ lower limit of quantification \[LLOQ\]) qRT-PCR measurements (reported on 2 or more independent samples over 2 days), from Day 2 up to Day 12. The number of participants with qRT-PCR-confirmed RSV infection is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Number · Percentage of Participants
Panel A vs. Panel C: Percentage of Participants With Respiratory Syncytial Virus (RSV) Infection Based on qRT-PCR
Percentage of ParticipantsPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: Percentage of Participants With Respiratory Syncytial Virus (RSV) Infection Based on qRT-PCR68.42 (51.35 to 82.50)65.00 (48.32 to 79.37)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · Difference in percent (%): 3.42 · 95% CI -18.28 to 24.50
SecondaryPanel A vs. Panel C: Percentage of Participants With RSV Infection Based on Cell Culture Measurement of Nasal Sample

RSV infection based on cell culture measurement was defined as at least one positive (≥ LLOQ) cell culture measurement in nasal swab samples. The percentage of participants with at least one positive (≥ LLOQ) cell culture measurement in nasal swab samples is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Number · Percentage of Participants
Panel A vs. Panel C: Percentage of Participants With RSV Infection Based on Cell Culture Measurement of Nasal Sample
Percentage of ParticipantsPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: Percentage of Participants With RSV Infection Based on Cell Culture Measurement of Nasal Sample57.89 (40.82 to 73.69)55.00 (38.49 to 70.74)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · Difference in percent (%): 2.89 · 95% CI -19.37 to 25.69
SecondaryPanel A vs. Panel C: Percentage of Participants With qRT-PCR Confirmed Symptomatic RSV Infection

Symptomatic RSV infection was defined as 2 quantifiable (≥LLOQ) qRT-PCR measurements reported on 2 or more days and either one or more clinical symptoms of any grade from two different categories in the symptom scoring system (upper respiratory, lower respiratory, systemic) or one grade 2 symptom from any category. The percentage of participants with qRT-PCR-confirmed symptomatic RSV infection is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Number · Percentage of Participants
Panel A vs. Panel C: Percentage of Participants With qRT-PCR Confirmed Symptomatic RSV Infection
Percentage of ParticipantsPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: Percentage of Participants With qRT-PCR Confirmed Symptomatic RSV Infection47.37 (30.98 to 64.18)50.00 (33.80 to 66.20)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · Difference in percent (%): -2.63 · 95% CI -25.07 to 19.91
SecondaryPanel A vs. Panel C: Percentage of Participants With qRT-PCR Confirmed Moderately Severe Symptomatic RSV Infection

Moderately severe symptomatic RSV infection was defined as 2 quantifiable (≥LLOQ) qRT-PCR measurements reported on 2 or more consecutive days and any symptom scores of grade ≥2 at a single time point. The percentage of participants with qRT-PCR-confirmed moderately severe symptomatic RSV infection is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Number · Percentage of Participants
Panel A vs. Panel C: Percentage of Participants With qRT-PCR Confirmed Moderately Severe Symptomatic RSV Infection
Percentage of ParticipantsPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: Percentage of Participants With qRT-PCR Confirmed Moderately Severe Symptomatic RSV Infection26.32 (13.40 to 43.10)42.50 (27.04 to 59.11)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · Difference in percent (%): -16.18 · 95% CI -36.77 to 5.64
SecondaryPanel A vs. Panel C: Percentage of Participants With Culture-Confirmed Symptomatic RSV Infection

Culture-confirmed symptomatic RSV infection was defined by 1 quantifiable (≥LLOQ) cell culture measurement from Day 2 up to Day 12, and either one or more clinical symptoms of any grade from two different categories in the symptom scoring system (upper respiratory, lower respiratory, systemic) or one grade 2 symptom from any category. The percentage of participants with culture confirmed symptomatic RSV infection is reported. Per protocol, only Panel A (prophylaxis) and Panel C (placebo) were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Number · Percentage of Participants
Panel A vs. Panel C: Percentage of Participants With Culture-Confirmed Symptomatic RSV Infection
Percentage of ParticipantsPanel A: Molnupiravir ProphylaxisPanel C: Matched Placebo
Panel A vs. Panel C: Percentage of Participants With Culture-Confirmed Symptomatic RSV Infection42.11 (26.31 to 59.18)45.00 (29.26 to 61.51)
Statistical analysis
  • Panel A: Molnupiravir Prophylaxis vs Panel C: Matched Placebo · Difference in percent (%): -2.89 · 95% CI -25.69 to 19.37
SecondaryPanel B vs. Panel C: PVL Determined by Viral Quantitative Culture

PVL was defined as the maximum viral load during a specified time period. PVL as determined by viral quantitative culture was measured starting from Day 2 up to planned discharge from quarantine (Day 12 am). PVL (on the log10 scale) of RSV A Memphis 37b determined by viral quantitative culture (plaque assay) between Day 2 and Day 12 am after intranasal inoculation (Day 0) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Least squares mean · log10 PFU/mL
Panel B vs. Panel C: PVL Determined by Viral Quantitative Culture
log10 PFU/mLPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: PVL Determined by Viral Quantitative Culture2.85 (1.96 to 3.74)3.53 (2.74 to 4.33)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · ANOVA · p = 0.253 · Difference in least squares mean: -0.69 · 90% CI -1.68 to 0.31
SecondaryPanel B vs. Panel C: Time to Negative Test by Viral Quantitative Culture

The time to negative test was defined as length of time in days between the date and time of the first MK-4482 administration to the date and time of first confirmed negative test after peak viral culture measurement. A negative test is a result below the low limit of quantification (LLOQ) by viral quantitative culture (plaque assay). The Kaplan-Meier estimate median in days is reported. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Median · Days
Panel B vs. Panel C: Time to Negative Test by Viral Quantitative Culture
DaysPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: Time to Negative Test by Viral Quantitative Culture5.0 (4.0 to NA)5.0 (4.0 to 6.0)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · Log Rank · p = 0.1708 · Hazard ratio (hr): 1.72 · 95% CI 0.83 to 3.57Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryPanel B vs. Panel C: VL-AUC Determined by qRT-PCR

VL-AUC between Day 2 and Day 12 after intranasal inoculation (Day 0) was computed for each participant, based on RSV viral load determined by qRT-PCR from nasal wash samples collected twice daily (morning and evening). In order to calculate the AUC, the actual time that the assessment was collected was used within the AUC calculation. VL-AUC (on the log10 scale) was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Least squares mean · days*log10 copies/mL
Panel B vs. Panel C: VL-AUC Determined by qRT-PCR
days*log10 copies/mLPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: VL-AUC Determined by qRT-PCR20.58 (13.00 to 28.16)26.51 (19.38 to 33.64)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · ANOVA · p = 0.257 · Difference in least squares mean: -5.93 · 90% CI -14.61 to 2.75
SecondaryPanel B vs. Panel C: PVL Determined by qRT-PCR

PVL was defined as the maximum viral load during a specified time period. PVL as determined by qRT-PCR was measured starting from Day 2 up to planned discharge from quarantine (Day 12 am). Nasal wash samples were collected and tested for RSV viral load by qRT-PCR twice daily from Day 2 through Day 11. A single nasal wash sample for RSV viral load by qRT-PCR was collected on Day 12. PVL by qRT-PCR were analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Least squares mean · log10 PFU/mL
Panel B vs. Panel C: PVL Determined by qRT-PCR
log10 PFU/mLPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: PVL Determined by qRT-PCR5.43 (4.30 to 6.56)6.02 (4.95 to 7.08)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · ANOVA · p = 0.453 · Difference in least squares mean: -0.58 · 90% CI -1.88 to 0.71
SecondaryPanel B vs. Panel C: Time to Negative Test by qRT-PCR

The time (days) to confirmed negative test by qRT-PCR was defined as the length of time between the date and time of the first investigational medicinal product (IMP) administration to the date and time of first confirmed undetectable (\<LLOQ) qRT-PCR result after peak qRT-PCR measurement. The time to negative test starting at Day 2 to first confirmed undetectable (\<LLOQ) assessment after peak measure is reported. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

Time frame:
From Day 2 up to Day 12
Reported as:
Median · Days
Panel B vs. Panel C: Time to Negative Test by qRT-PCR
DaysPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: Time to Negative Test by qRT-PCRNA (6.0 to NA)9.0 (7.0 to NA)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · Log Rank · p = 0.9121 · Hazard ratio (hr): 1.06 · 95% CI 0.44 to 2.51Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryPanel B vs. Panel C: TSS-AUC

Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). Total symptom scores (TSS) ranged from 0 to 31, with higher scores indicating greater symptom severity. TSS were used to calculate the AUC for each participant based on the available non-missing calculated total symptom scores between Day -1 until Day 12 (quarantine discharge) using the Trapezoidal rule. TSS-AUC was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B and Panel C are included in the model, and only participants with RSV infection were included in the analysis. TSS-AUC measured from 10 symptoms within the graded symptom scoring was reported.

Time frame:
From Day -1 up to Day 12
Reported as:
Least squares mean · Scores on a Scale*Days
Panel B vs. Panel C: TSS-AUC
Scores on a Scale*DaysPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: TSS-AUC4.74 (1.76 to 7.72)6.57 (3.76 to 9.37)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · ANOVA · p = 0.377 · Difference in least squares mean: -1.83 · 90% CI -5.25 to 1.60
SecondaryPanel B vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores Change From Baseline (TSS-AUC-CFB)

Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("absence") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. TSS were used to calculate the AUC for each participant based on the available non-missing calculated total symptom scores between Day -1 until Day 12 (quarantine discharge) using the Trapezoidal rule. TSS-AUC-CFB was analyzed using a linear model with treatment group as a fixed categorical effect. Per protocol, only Panel B and Panel C are included in the model, and only the participants with RSV infection were included in the analysis. TSS-AUC-CFB was defined as the change from baseline in TSS-AUC from Day -1 up to Day 12. TSS-AUC-CFB measured from 10 symptoms within the graded symptom scoring was reported.

Time frame:
Baseline (Day -1) and up to Day 12
Reported as:
Least squares mean · Scores on a Scale*Days
Panel B vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores Change From Baseline (TSS-AUC-CFB)
Scores on a Scale*DaysPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: Area Under the Curve Over Time of Total Symptom Scores Change From Baseline (TSS-AUC-CFB)2.60 (-1.02 to 6.23)2.74 (-0.67 to 6.15)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · ANOVA · p = 0.958 · Difference in least squares mean: -0.13 · 90% CI -4.28 to 4.02
SecondaryPanel B vs. Panel C: Peak TSS

Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. The highest total symptom score (defined as the sum of all 10 individual composite symptoms) was summarized by treatment group and analyzed using a linear model with treatment group as a fixed categorical effect. Peak TSS measured from 10 symptoms within the graded symptom scoring was reported for Panels B and C. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

Time frame:
From Day -1 up to Day 12
Reported as:
Least squares mean · Score on a Scale
Panel B vs. Panel C: Peak TSS
Score on a ScalePanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: Peak TSS3.00 (1.61 to 4.39)3.62 (2.31 to 4.92)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · ANOVA · p = 0.520 · Difference in least squares mean: -0.62 · 90% CI -2.21 to 0.98
SecondaryPanel B vs. Panel C: Peak Daily Symptom Score

Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. The highest total symptom score recorded on each day, across the three assessments, for each participant was summarized descriptively by treatment group and assessment day. Peak daily sums of symptom score measured from 10 symptoms within the graded symptom scoring were reported for Panels B and C. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

Time frame:
From Day -1 up to Day 12
Reported as:
Mean · Score on a Scale
Panel B vs. Panel C: Peak Daily Symptom Score
Score on a ScalePanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Day 10.6 ± 0.901.4 ± 1.6
Day 21.3 ± 1.892.0 ± 2.18
Day 31.5 ± 1.682.3 ± 2.31
Day 42.1 ± 2.442.7 ± 3.26
Day 51.8 ± 2.672.5 ± 3.37
Day 61.4 ± 2.291.5 ± 2.06
Day 70.7 ± 1.331.2 ± 2.12
Day 80.5 ± 1.080.7 ± 1.48
Day 91.0 ± 1.260.8 ± 1.42
Day 100.7 ± 1.150.5 ± 1.00
Day 111.0 ± 1.410.0 ± 0
SecondaryPanel B vs. Panel C: Time to Symptom Resolution

Participants used a symptom diary card to record the daily severity of 10 clinical symptoms on a scale ranging from 0 ("no symptoms") to 3 ("bothersome and interferes with activities"), with the exception of "shortness of breath" symptom which was scored from 0 ("no symptoms") to 4 ("symptoms at rest"). TSS ranged from 0 to 31, with higher scores indicating greater symptom severity. Symptom resolution was defined as a participant scoring 0 for the total symptom score for a 24-hour period (e.g., a minimum of three consecutive symptom diary cards, each with a score of 0 after their peak symptom score. The time in days to symptom resolution by treatment group, as measured from 10 symptoms within the graded daily symptom scoring system, was reported. Per protocol, only Panel B (treatment) and Panel C (placebo) are included in the model. For both panels, only the participants with RSV infection were included in the analysis.

Time frame:
From Day -1 up to Day 12
Reported as:
Least squares mean · Days
Panel B vs. Panel C: Time to Symptom Resolution
DaysPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Panel B vs. Panel C: Time to Symptom Resolution6.0 (4.0 to 8.0)8.5 (6.0 to NA)
Statistical analysis
  • Panel B: Molnupiravir Triggered Treatment vs Panel C: Matched Placebo · Log Rank · p = 0.0459 · Hazard ratio (hr): 2.24 · 95% CI 0.99 to 5.07Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryPanels A & B: Maximum Plasma Concentration (Cmax) of N-Hydroxycytidine (NHC)

NHC is the pharmacologically active moiety of molnupiravir and therefore its primary pharmacokinetic measure. Cmax was defined as the peak concentration of NHC over the dosing interval. Plasma samples were collected at multiple time points pre-and post-administration and used to determine Cmax. Cmax of NHC was reported for participants receiving molnupiravir in Panels A and B.

Time frame:
Day -1: Predose and 12 hours postdose; Days 2, 5, and 6: 12 hours postdose; Days 4 and 7: predose and 0.5, 1.5, 4, 8, and 12 hours postdose
Reported as:
Geometric mean · ng/mL
Panels A & B: Maximum Plasma Concentration (Cmax) of N-Hydroxycytidine (NHC)
ng/mLPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered Treatment
Panels A & B: Maximum Plasma Concentration (Cmax) of N-Hydroxycytidine (NHC)3640 ± 33.53010 ± 111.5
SecondaryPanels A & B: Time to Maximum Plasma Concentration (Tmax) of NHC

NHC is the pharmacologically active moiety of molnupiravir and therefore its primary pharmacokinetic measure. Tmax was defined as the time to peak concentration. Plasma samples were collected at multiple time points pre-and post-administration and used to determine Tmax. Tmax of NHC was reported for participants receiving molnupiravir in Panels A and B.

Time frame:
Day -1: Predose and 12 hours postdose; Days 2, 5, and 6: 12 hours postdose; Days 4 and 7: predose and 0.5, 1.5, 4, 8, and 12 hours postdose
Reported as:
Median · hr
Panels A & B: Time to Maximum Plasma Concentration (Tmax) of NHC
hrPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered Treatment
Panels A & B: Time to Maximum Plasma Concentration (Tmax) of NHC1.47 (1.33 to 1.97)1.48 (0.00 to 2.13)
SecondaryPanels A & B: Area Under the Plasma Concentration Curve From 0 to 12 Hours Postdose (AUC0-12) of NHC

NHC is the pharmacologically active moiety of molnupiravir and therefore its primary pharmacokinetic measure. Plasma samples were collected at multiple time points pre-and post-administration and used to determine the area under the plasma concentration curve from time 0 to 12 hours (AUC0-12). AUC0-12 was reported for participants receiving molnupiravir in Panels A and B.

Time frame:
Day -1: Predose and 12 hours postdose; Days 2, 5, and 6: 12 hours postdose; Days 4 and 7: predose and 0.5, 1.5, 4, 8, and 12 hours postdose
Reported as:
Geometric mean · hr*ng/mL
Panels A & B: Area Under the Plasma Concentration Curve From 0 to 12 Hours Postdose (AUC0-12) of NHC
hr*ng/mLPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered Treatment
Panels A & B: Area Under the Plasma Concentration Curve From 0 to 12 Hours Postdose (AUC0-12) of NHC9270 ± 28.48100 ± 87.9
SecondaryPanels A & B: Trough Concentration (Ctrough) of NHC

NHC is the pharmacologically active moiety of molnupiravir and therefore its primary pharmacokinetic measure. The trough concentration (Ctrough) was defined as the lowest concentration before the next dose. Plasma samples were collected at multiple time points pre-and post-administration and used to determine Cmax. Ctrough of NHC in plasma was reported for participants receiving molnupiravir in Panels A and B.

Time frame:
Day 2 at 12 hours predose (Panel A) or Day 6 at 12 hours predose (Panel B)
Reported as:
Geometric mean · ng/mL
Panels A & B: Trough Concentration (Ctrough) of NHC
ng/mLPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered Treatment
Panels A & B: Trough Concentration (Ctrough) of NHC25.1 ± 55.619.8 ± 66.8

Adverse events

Collected over Day -1 up to Day 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A: Molnupiravir Prophylaxis0/40 (0%)0/39 (0%)1/39 (2.6%)
Panel B: Molnupiravir Triggered Treatment0/36 (0%)0/36 (0%)2/36 (5.6%)
Panel C: Matched Placebo0/40 (0%)0/40 (0%)0/40 (0%)
Most frequent other events
Most frequent other events
EventPanel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched Placebo
Upper respiratory tract infectionInfections and infestations1/392/360/40

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched PlaceboTotal
Mean26.6 ± 5.428.7 ± 8.226.8 ± 6.927.3 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched PlaceboTotal
Female15131745
Male25232371
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Panel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched PlaceboTotal
Hispanic or Latino0101
Not Hispanic or Latino403540115
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Panel A: Molnupiravir ProphylaxisPanel B: Molnupiravir Triggered TreatmentPanel C: Matched PlaceboTotal
American Indian or Alaska Native0000
Asian3328
Native Hawaiian or Other Pacific Islander0000
Black or African American44715
White32252986
More than one race1427
Unknown or Not Reported0000
08

Study locations

1 site
  • hVIVO Services ( Site 0001)
    London, London, City of E1 2AX, United Kingdom
09

References and documents

Publications

  • Cheng MH, Mann AJ, Maas BM, Zhao T, Bevan M, Schaeffer AK, Liao LE, Catchpole AP, Hilbert DW, Aubrey Stoch S, De Anda CS. A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus. Pulm Ther. 2025 Jun;11(2):285-304. doi: 10.1007/s41030-025-00289-z. Epub 2025 Apr 2. PubMed 40175624 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Apr 2023, 5 months.

Results were first posted in May 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Sep 29, 2022
StartActual
Nov 2, 2022
Primary completionActual
Apr 18, 2023
CompletionActual
Jun 8, 2023
Results first posted
May 20, 2024
Last update
Jul 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05559905
Responsible party
Sponsor
First posted
Sep 29, 2022
Start date
Nov 2, 2022
Primary completion
Apr 18, 2023
Completion
Jun 8, 2023
Results posted
May 20, 2024
Last update
Jul 18, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion